Search for "thiazoles" in Full Text gives 49 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2017, 13, 2862–2868, doi:10.3762/bjoc.13.278
Graphical Abstract
Scheme 1: Reported Pd-catalyzed heteroarylations of bromoselenophenes.
Scheme 2: Palladium-catalyzed heteroarylations of 2-bromoselenophene. *: 110 °C
Scheme 3: Palladium-catalyzed 2,5-diheteroarylation of 2,5-dibromoselenophene.
Scheme 4: Synthesis of 2-aryl-5-(heteroaryl)selenophenes.
Scheme 5: Proposed catalytic cycle.
Beilstein J. Org. Chem. 2017, 13, 2739–2750, doi:10.3762/bjoc.13.270
Graphical Abstract
Scheme 1: Two different intermolecular cyclization pathways controlled by reagents used.
Scheme 2: Scope of reaction. Reaction conditions: 1 (1.2 mmol), 2 (1.0 mmol), KOt-Bu (2 mmol), in 3 mL CBrCl3...
Scheme 3: Scope of the reaction. Reaction conditions: 1 (1.0 mmol), 2 (1.5 mmol), In(OTf)3 (0.1 mmol), in 1.5...
Scheme 4: Control experiments.
Figure 1: Proposed mechanism (benzo[d]imidazo[2,1-b]thiazoles).
Figure 2: Proposed mechanism (benzo[4,5]thiazolo[3,2-a]pyrimidin-4-ones).
Beilstein J. Org. Chem. 2017, 13, 1670–1692, doi:10.3762/bjoc.13.162
Graphical Abstract
Figure 1: Representative bioactive heterocycles.
Scheme 1: The concept of oxidative dehydrogenation.
Scheme 2: IBX-mediated oxidative dehydrogenation of various heterocycles [31-34].
Scheme 3: Potential mechanism of IBX-mediated oxidative dehydrogenation of N-heterocycles [31-34].
Scheme 4: IBX-mediated room temperature one-pot condensation–oxidative dehydrogenation of o-aminobenzylamines....
Scheme 5: Anhydrous cerium chloride-catalyzed, IBX-mediated oxidative dehydrogenation of various heterocycles...
Scheme 6: Oxidative dehydrogenation of quinazolinones with I2 and DDQ [37-40].
Scheme 7: DDQ-mediated oxidative dehydrogenation of thiazolidines and oxazolidines.
Scheme 8: Oxone-mediated oxidative dehydrogenation of intermediates from o-phenylenediamine and o-aminobenzyl...
Scheme 9: Transition metal-free oxidative cross-dehydrogenative coupling.
Scheme 10: NaOCl-mediated oxidative dehydrogenation.
Scheme 11: NBS-mediated oxidative dehydrogenation of tetrahydro-β-carbolines.
Scheme 12: One-pot synthesis of various methyl(hetero)arenes from o-aminobenzamide in presence of di-tert-buty...
Scheme 13: Oxidative dehydrogenation of 1, 4-DHPs.
Scheme 14: Synthesis of quinazolines in the presence of MnO2.
Scheme 15: Selenium dioxide and potassium dichromate-mediated oxidative dehydrogenation of tetrahydro-β-carbol...
Scheme 16: Synthesis of substituted benzazoles in the presence of barium permanganate.
Scheme 17: Oxidative dehydrogenation with phenanthroline-based catalysts. PPTS = pyridinium p-toluenesulfonic ...
Scheme 18: Oxidative dehydrogenation with Flavin mimics.
Scheme 19: o-Quinone based bioinspired catalysts for the synthesis of dihydroisoquinolines.
Scheme 20: Cobalt-catalyzed aerobic dehydrogenation of Hantzch 1,4-DHPs and pyrazolines.
Scheme 21: Mechanism of cobalt-catalyzed aerobic dehydrogenation of Hantzch 1,4-DHPs.
Scheme 22: DABCO and TEMPO-catalyzed aerobic oxidative dehydrogenation of quinazolines and 4H-3,1-benzoxazines....
Scheme 23: Putative mechanism for Cu(I)–DABCO–TEMPO catalyzed aerobic oxidative dehydrogenation of tetrahydroq...
Scheme 24: Potassium triphosphate modified Pd/C catalysts for the oxidative dehydrogenation of tetrahydroisoqu...
Scheme 25: Ruthenium-catalyzed polycyclic heteroarenes.
Scheme 26: Plausible mechanism of the ruthenium-catalyzed dehydrogenation.
Scheme 27: Bi-metallic platinum/iridium alloyed nanoclusters and 5,5’,6,6’-tetrahydroxy-3,3,3’,3’-tetramethyl-...
Scheme 28: Magnesium iodide-catalyzed synthesis of quinazolines.
Scheme 29: Ferrous chloride-catalyzed aerobic dehydrogenation of 1,2,3,4-tetrahydroquinolines.
Scheme 30: Cu(I)-catalyzed oxidative aromatization of indoles.
Scheme 31: Putative mechanism of the transformation.
Scheme 32: Oxidative dehydrogenation of pyrimidinones and pyrimidines.
Scheme 33: Putative mechanisms (radical and metal-catalyzed) of the transformation.
Scheme 34: Ferric chloride-catalyzed, TBHP-oxidized synthesis of substituted quinazolinones and arylquinazolin...
Scheme 35: Iridium-catalyzed oxidative dehydrogenation of quinolines.
Scheme 36: Microwave-assisted synthesis of β-carboline with a catalytic amount of Pd/C in lithium carbonate at...
Scheme 37: 4-Methoxy-TEMPO-catalyzed aerobic oxidative synthesis of 2-substituted benzazoles.
Scheme 38: Plausible mechanism of the 4-methoxy-TEMPO-catalyzed transformation.
Scheme 39: One-pot synthesis of 2-arylquinazolines, catalyzed by 4-hydroxy-TEMPO.
Scheme 40: Oxidative dehydrogenation – a key step in the synthesis of AZD8926.
Scheme 41: Catalytic oxidative dehydrogenation of tetrahydroquinolines to afford bioactive molecules.
Scheme 42: Iodobenzene diacetate-mediated synthesis of β-carboline natural products.
Beilstein J. Org. Chem. 2017, 13, 1050–1063, doi:10.3762/bjoc.13.104
Graphical Abstract
Scheme 1: Aminoazoles in GBB-3CR and Ugi-4CR.
Scheme 2: Reactivity of 5-amino-N-aryl-1H-pyrazole-4-carboxamide and 3-amino-5-methylisoxazole in GBB-3CR and...
Figure 1: Alternative structures A and B for compounds 4 and 6.
Figure 2: Selected data of HSQC and HMBC experiments for compound 4a.
Figure 3: Molecular structure of 3-(tert-butylamino)-2-(4-chlorophenyl)-N-(4-fluorophenyl)-1H-imidazo[1,2-b]p...
Figure 4: Selected data of NOE and HSQC experiments for compound 9d.
Figure 5: Molecular structure of N-(2-(tert-butylamino)-1-(4-chlorophenyl)-2-oxoethyl)-N-(5-methylisoxazol-3-...
Beilstein J. Org. Chem. 2017, 13, 625–638, doi:10.3762/bjoc.13.61
Graphical Abstract
Figure 1: Selected examples of bioactive thiazole derivatives.
Figure 2: Some natural sources of thiazoles.
Figure 3: Some important thiazole-based compounds derived from N-propargylamines.
Scheme 1: The synthesis of thiazole-2-thiones 3 through the thermal cyclocondensation of N-propargylamines 1 ...
Scheme 2: (a) One-pot synthesis of 2-benzylthiazolo[3,2-a]benzimidazoles 6 through a base-catalyzed cascade r...
Scheme 3: (a) Synthesis of 2-iminothiazolidines 11 from N-propargylamines 9 and isothiocyanates 10. (b) Synth...
Scheme 4: (a) Synthesis of 2-aminothiazoles 17 through the reaction of ethyl 4-aminobut-2-ynoate salts 15 wit...
Scheme 5: Synthesis of 5-(iodomethylene)-3-methylthiazolidines 27 described by Zhou.
Scheme 6: Mechanism that accounts for the formation of 27.
Scheme 7: Clausen’s synthesis of fluorescein thiazolidines 30.
Scheme 8: Synthesis of multiply substituted thiazolidines 33 from N-propargylamines 32 and blocked N-isothioc...
Scheme 9: (a) Microwave-assisted cyclization of N-propargyl thiocarbamate 34. (b) Synthesis of thiazoles 39 t...
Scheme 10: Synthesis of thiazolidines 42 (42’) from the reaction of β-oxodithioesters 40 (40’) with N-propargy...
Scheme 11: Synthesis of 5-(dibromomethyl)thiazoles 44 via halocyclization of N-propargylamines 43 described by...
Scheme 12: Synthesis of dihydrothiazoles 46 through the treatment of N-propargylamides 45 with Lawesson’s reag...
Scheme 13: Synthesis of thiazoles 49 by treatment of silyl-protected N-propargylamines 47 with benzotriazolylt...
Scheme 14: Mechanism proposed to explain the synthesis of 2,5-disubstituted thiazoles 49 developed by Sasmal.
Scheme 15: Mo-catalyzed cyclization of N-propargylthiocarbamate 50.
Scheme 16: (a) DABCO-mediated intramolecular cyclization of N-(propargylcarbamothioyl)amides 53 to the corresp...
Scheme 17: Proposed mechanism for the generation of the iodine-substituted 4H-1,3-thiazines 56 and 4,5-dihydro...
Scheme 18: Au(III)-catalyzed synthesis of 5-alkylidenedihydrothiazoles 58 developed by Stevens.
Beilstein J. Org. Chem. 2016, 12, 1250–1268, doi:10.3762/bjoc.12.120
Graphical Abstract
Figure 1: Schematic of RiPP biosynthesis. Thiazole/oxazole formation is represented by the blue heterocycle (...
Figure 2: Examples of heterocycles in RiPPs alongside the precursor peptides that these molecules derive from...
Figure 3: Formation of thiazoles and oxazoles in RiPPs. A) Biosynthesis of microcin B17. B) Mechanistic model...
Figure 4: Lanthionine bond formation. A) Nisin and its precursor peptide. B) Mechanism of lanthionine bond fo...
Figure 5: S-[(Z)-2-Aminovinyl]-D-cysteine (AviCys) formation in the epidermin pathway. A) Mechanisms for deca...
Figure 6: Cyclisation in the biosynthesis of thiopeptides. A) Mechanism of TclM-catalysed heterocyclisation i...
Figure 7: ATP-dependent macrocyclisation. A) General mechanism for ATP-dependent macrolactonisation or macrol...
Figure 8: Peptidase-like macrolactam formation. A) General mechanism. B) Examples of RiPPs cyclised by serine...
Figure 9: Structure of autoinducing peptide AIP-I from Staphylococcus aureus and the sequence of the correspo...
Figure 10: Radical cyclisation in RiPP biosynthesis. A) AlbA-catalysed formation of thioethers in the biosynth...
Figure 11: RiPPs with uncharacterised mechanisms of cyclisation. Unusual heterocycles in ComX and methanobacti...
Beilstein J. Org. Chem. 2015, 11, 2223–2241, doi:10.3762/bjoc.11.241
Graphical Abstract
Figure 1: Some ruthenium catalysts for metathesis reactions.
Scheme 1: Decomposition of methylidenes 1 and 2.
Scheme 2: Deactivation of G-HII in the presence of ethylene.
Scheme 3: Reaction between GI/GII and n-BuNH2.
Scheme 4: Reaction of GII with amines a–d.
Scheme 5: Amine-induced decomposition of GII methylidene 2.
Scheme 6: Amine-induced decomposition of GII in RCM conditions.
Scheme 7: Deactivation of methylidene 2 in the presence of pyridine.
Scheme 8: Reaction of G-HII with various amines.
Scheme 9: Formation of olefin 22 from styrene.
Scheme 10: Hypothetic deactivation pathway of G-HII.
Scheme 11: RCM of dienic pyridinium salts.
Scheme 12: Synthesis of polycyclic scaffolds using RCM.
Scheme 13: Enyne ring-closing metathesis.
Scheme 14: Synthesis of (R)-(+)-muscopyridine using a RCM strategy.
Scheme 15: Synthesis of a tris-pyrrole macrocycle.
Scheme 16: Synthesis of a bicyclic imidazole.
Scheme 17: RCM using Schrock’s catalyst 44.
Scheme 18: Synthesis of 1,6-pyrido-diazocine 46 by using a RCM.
Scheme 19: Synthesis of fused pyrimido-azepines through RCM.
Scheme 20: RCM involving alkenes containing various N-heteroaromatics.
Scheme 21: Synthesis of dihydroisoquinoline using a RCM.
Scheme 22: Formation of tricyclic compound 59.
Scheme 23: RCM in the synthesis of normuscopyridine.
Scheme 24: Synthesis of macrocycle 64.
Scheme 25: Synthesis of macrocycles possessing an imidazole group.
Scheme 26: Retrosynthesis of an analogue of erythromycin.
Scheme 27: Retrosynthesis of haminol A.
Scheme 28: CM involving 3-vinylpyridine 70 with 71 and vinylpyridine 70 with 73.
Scheme 29: Revised retrosynthesis of haminol A.
Scheme 30: CM between 78 and crotonaldehyde.
Scheme 31: Hypothesized deactivation pathway.
Scheme 32: CM involving an allyl sulfide containing a quinoline.
Scheme 33: CM involving allylic sulfide possessing a quinoxaline or a phenanthroline.
Scheme 34: CM between an acrylate and a 2-methoxy-5-bromo pyridine.
Scheme 35: Successful CM of an alkene containing a 2-chloropyridine.
Scheme 36: Variation of the substituent on the pyridine ring.
Scheme 37: CM involving alkenes containing a variety of N-heteroaromatics.
Beilstein J. Org. Chem. 2015, 11, 2132–2144, doi:10.3762/bjoc.11.230
Graphical Abstract
Scheme 1: Copper-catalyzed C–H bond halogenation of 2-arylpyridine.
Scheme 2: ortho-Chlorination of 2-arylpridines with acyl chlorides.
Scheme 3: Copper-catalyzed chlorination of 2-arylpyridines using LiCl.
Scheme 4: Copper-catalyzed C–H halogenation of 2-arylpyridines using LiX.
Scheme 5: Copper-mediated selective C–H halogenations of 2-arylpyridine.
Scheme 6: Copper-catalyzed C–H o-halogenation using removable DG.
Scheme 7: Copper-catalyzed C–H halogenations using PIP as DG.
Scheme 8: Copper-catalyzed quinoline C–H chlorination.
Scheme 9: Copper-catalyzed arene C–H fluorination of benzamides.
Scheme 10: Copper-catalyzed arene C–H iodination of 1,3-azoles.
Scheme 11: Copper-catalyzed C–H halogenations of phenols.
Scheme 12: Proposed mechanism for the C–H halogenation of phenols.
Scheme 13: Copper-catalyzed halogenation of electron enriched arenes.
Scheme 14: Copper-catalyzed C–H bromination of arenes.
Scheme 15: CuI-mediated synthesis of iododibenzo[b,d]furans via C–H functionalization.
Scheme 16: Cu-Mn spinel oxide-catalyzed phenol and heteroarene halogenation.
Scheme 17: Copper-catalyzed halogenations of 2-amino-1,3thiazoles.
Scheme 18: Copper-mediated chlorination and bromination of indolizines.
Scheme 19: Copper-catalyzed three-component synthesis of bromoindolizines.
Scheme 20: Copper-mediated C–H halogenation of azacalix[1]arene[3]pyridines.
Scheme 21: Copper-mediated cascade synthesis of halogenated pyrrolones.
Scheme 22: Copper-mediated alkene C–H chlorination in spirothienooxindole.
Scheme 23: Copper-catalyzed remote C–H chlorination of alkyl hydroperoxides.
Scheme 24: Copper-catalyzed C–H fluorination of alkanes.
Scheme 25: Copper-catalyzed or mediated C–H halogenations of active C(sp3)-bonds.
Beilstein J. Org. Chem. 2015, 11, 2021–2028, doi:10.3762/bjoc.11.219
Graphical Abstract
Figure 1: Formation of substituted aziridine.
Figure 2: Various strategies for the formation of 2H-azirine.
Scheme 1: Attempted reaction for the synthesis of 3a.
Figure 3: Synthesis of α-amido-1,3-diketone (3a–o). Reaction conditions: α-azidochalcone 1 (1.0 equiv) and ca...
Scheme 2: Plausible mechanism.
Scheme 3: Attempted reaction with acid derivatives.
Scheme 4: Oxazole formation from 3.
Figure 4: Possible isomers for 7.
Scheme 5: Oxazole formation.
Figure 5: Synthesis of highly substituted 2-(trifluoromethyl)oxazoles (8a–e). Reaction conditions: α-azidocha...
Scheme 6: Mechanism for the formation of 8.
Beilstein J. Org. Chem. 2015, 11, 2012–2020, doi:10.3762/bjoc.11.218
Graphical Abstract
Figure 1: Different pathways for the synthesis of π-conjugated molecules incorporating fluorinated phenylene ...
Scheme 1: Pd-catalyzed desulfitative direct arylations of heteroarenes using 2,3,4-trifluorobenzenesulfonyl c...
Scheme 2: Pd-catalyzed second arylation of 1 and 2. i) PdCl(C3H5)(dppb) (2 mol %), KOAc (2 equiv), DMA, 150 °...
Scheme 3: Pd-catalyzed direct regioselective arylation of 1-methyl-2-(2,3,4-trifluorophenyl)pyrrole (4). i) P...
Scheme 4: Pd-catalyzed direct regioselective arylation of 3-(2,3,4-trifluorophenyl)thiophenes. i) PdCl(C3H5)(...
Scheme 5: Pd-catalyzed desulfitative direct arylations of heteroarenes using difluorobenzenesulfonyl chloride...
Scheme 6: Pd-catalyzed second direct regioselective arylation of difluorophenylheteroarenes 19-23. i) PdCl(C3H...
Scheme 7: Pd-catalyzed iterative direct arylations of heteroarenes–fluorobenzene triads and tetrad. i) PdCl2(...
Scheme 8: Reactivity of pentafluorobenzenesulfonyl chloride in Pd-catalyzed direct desulfitative arylation of...
Beilstein J. Org. Chem. 2015, 11, 1148–1154, doi:10.3762/bjoc.11.129
Graphical Abstract
Figure 1: Compounds 1–3.
Scheme 1: Synthesis of compound 4.
Scheme 2: Synthesis of compounds 1 and 2.
Figure 2: UV–vis absorption spectra of 10−5 M solutions of compounds 1 (black) and 2 (red) in dichloromethane....
Figure 3: Cyclic voltammograms showing the reduction (left) and oxidation (right) of compounds 1 (top) and 2 ...
Figure 4: Optimised structures of 1 (left), 2 (centre) and 3 (right).
Figure 5: Output characteristics of OFETs fabricated using compound 2 in CHCl3 with OTS (top) and PFBT/OTS (b...
Figure 6: AFM images of OFET devices fabricated using compound 2 in CHCl3 with OTS (left) and PFBT/OTS (right...
Beilstein J. Org. Chem. 2015, 11, 875–883, doi:10.3762/bjoc.11.98
Graphical Abstract
Figure 1: Selected examples of biologically active thiazole containing molecules [12-20].
Scheme 1: Illustration of substrates that form thiophenes under Gewald-type conditions.
Figure 2: Substrates which did not react under the optimised conditions.
Scheme 2: Proposed mechanisms for the formation of thiazoles.
Beilstein J. Org. Chem. 2014, 10, 2912–2919, doi:10.3762/bjoc.10.309
Graphical Abstract
Figure 1: 2,2':5',2"-Terthiophene.
Scheme 1: Palladium-catalyzed direct arylation using 2,5-dibromothiophene and 2-ethyl-4-methylthiazole as cou...
Scheme 2: Reactivity of 2,5-dibromothiophene with different heteroarenes.
Scheme 3: Reactivity of 2,5-dibromo-3-methylthiophene with different heteroarenes.
Scheme 4: Sequential diheteroarylation of 2,5-dibromothiophene.
Scheme 5: Sequential diheteroarylation of 2,5-dibromothiophene.
Scheme 6: Heteroarylation of 2-bromothiophene.
Scheme 7: Reactivity of 4,7-dibromobenzothiadiazole.
Beilstein J. Org. Chem. 2014, 10, 2470–2479, doi:10.3762/bjoc.10.258
Graphical Abstract
Figure 1: Structure of the reporter molecule BPT (1).
Scheme 1: Synthesis of the azide-bearing 4-hydroxythiazole derivative 1.
Figure 2: Structure of the tested azide-modified standard fluorophores DNS (8) and NBD (9) and the bromine mo...
Figure 3: UV–vis spectra of 20 µM solutions of the azide modified fluorophores BPT (1), DNS (8), NBD (9) and ...
Figure 4: Normalized absorbance and fluorescence of BPT (1) in 20% THF/80% water (v/v), excitation at 374 nm.
Figure 5: Peak area of 100 pmol BPT (1), DNS (8), NBD (9) and BNS (6) measured with (A) C18-UPLC coupled to a...
Figure 6: Procedure of the model reaction between L-lysine and DDY (10) to form an imine (only one of two pos...
Figure 7: Mass spectra of labeled L-lysine/DDY (10)/fluorophore conjugates 11 (containing BPT), 12 (containin...
Figure 8: Fluorescent labeling of catalase treated with DDY (10) followed by CuAAC with all four reporter mol...
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2013, 9, 2476–2536, doi:10.3762/bjoc.9.287
Graphical Abstract
Scheme 1: Pd-catalyzed monofluoromethylation of pinacol phenylboronate [44].
Scheme 2: Cu-catalyzed monofluoromethylation with 2-PySO2CHFCOR followed by desulfonylation [49].
Scheme 3: Cu-catalyzed difluoromethylation with α-silyldifluoroacetates [57].
Figure 1: Mechanism of the Cu-catalyzed C–CHF2 bond formation of α,β-unsaturated carboxylic acids through dec...
Scheme 4: Fe-catalyzed decarboxylative difluoromethylation of cinnamic acids [62].
Scheme 5: Preliminary experiments for investigation of the mechanism of the C–H trifluoromethylation of N-ary...
Figure 2: Plausible catalytic cycle proposed by Z.-J. Shi et al. for the trifluoromethylation of acetanilides ...
Figure 3: Plausible catalytic cycle proposed by M. S. Sanford et al. for the perfluoroalkylation of simple ar...
Figure 4: Postulated reaction pathway for the Ag/Cu-catalyzed trifluoromethylation of aryl iodides by Z. Q. W...
Figure 5: Postulated reaction mechanism for Cu-catalyzed trifluoromethylation reaction using MTFA as trifluor...
Scheme 6: Formal Heck-type trifluoromethylation of vinyl(het)arenes by M. Sodeoka et al. [83].
Figure 6: Proposed catalytic cycle for the copper-catalyzed trifluoromethylation of (het)arenes in presence o...
Figure 7: Proposed catalytic cycle for the copper-catalyzed trifluoromethylation of N,N-disubstituted (hetero...
Figure 8: Proposed catalytic cycle by Y. Zhang and J. Wang et al. for the copper-catalyzed trifluoromethylati...
Figure 9: Mechanistic rationale for the trifluoromethylation of arenes in presence of Langlois’s reagent and ...
Scheme 7: Trifluoromethylation of 4-acetylpyridine with Langlois’s reagent by P. S. Baran et al. (* Stirring ...
Scheme 8: Catalytic copper-facilitated perfluorobutylation of benzene with C4F9I and benzoyl peroxide [90].
Figure 10: F.-L. Qing et al.’s proposed mechanism for the copper-catalyzed trifluoromethylation of (hetero)are...
Figure 11: Mechanism of the Cu-catalyzed/Ru-photocatalyzed trifluoromethylation and perfluoroalkylation of ary...
Figure 12: Proposed mechanism for the Cu-catalyzed trifluoromethylation of aryl- and vinyl boronic acids with ...
Figure 13: Possible mechanism for the Cu-catalyzed decarboxylative trifluoromethylation of cinnamic acids [62].
Scheme 9: Ruthenium-catalyzed perfluoroalkylation of alkenes and (hetero)arenes with perfluoroalkylsulfonyl c...
Figure 14: N. Kamigata et al.’s proposed mechanism for the Ru-catalyzed perfluoroalkylation of alkenes and (he...
Figure 15: Proposed mechanism for the Ru-catalyzed photoredox trifluoromethylation of (hetero)arenes with trif...
Figure 16: Late-stage trifluoromethylation of pharmaceutically relevant molecules with trifluoromethanesulfony...
Figure 17: Proposed mechanism for the trifluoromethylation of alkenes with trifluoromethyl iodide under Ru-bas...
Scheme 10: Formal perfluoroakylation of terminal alkenes by Ru-catalyzed cross-metathesis with perfluoroalkyle...
Figure 18: One-pot Ir-catalyzed borylation/Cu-catalyzed trifluoromethylation of complex small molecules by Q. ...
Figure 19: Mechanistic proposal for the Ni-catalyzed perfluoroalkylation of arenes and heteroarenes with perfl...
Scheme 11: Electrochemical Ni-catalyzed perfluoroalkylation of 2-phenylpyridine (Y. H. Budnikova et al.) [71].
Scheme 12: Fe(II)-catalyzed trifluoromethylation of arenes and heteroarenes with trifluoromethyl iodide (T. Ya...
Figure 20: Mechanistic proposal by T. Yamakawa et al. for the Fe(II)-catalyzed trifluoromethylation of arenes ...
Scheme 13: Ytterbium-catalyzed perfluoroalkylation of dihydropyran with perfluoroalkyl iodide (Y. Ding et al.) ...
Figure 21: Mechanistic proposal by A. Togni et al. for the rhenium-catalyzed trifluoromethylation of arenes an...
Figure 22: Mechanism of the Cu-catalyzed oxidative trifluoromethylthiolation of arylboronic acids with TMSCF3 ...
Scheme 14: Removal of the 8-aminoquinoline auxiliary [136].
Figure 23: Mechanism of the Cu-catalyzed trifluoromethylthiolation of C–H bonds with a trifluoromethanesulfony...
Beilstein J. Org. Chem. 2013, 9, 577–584, doi:10.3762/bjoc.9.62
Graphical Abstract
Scheme 1: Retrosynthetic analysis of 2,3-dihydronaphtho[2,3-d][1,3]thiazole-4,9-diones and 2,3-dihydroanthra[...
Scheme 2: Reaction of 2-[butyl(methyl)amino]naphthoquinone 3a with S2Cl2 and Hünig’s base.
Scheme 3: Synthesis of 2,3-dihydronaphtho[2,3-d][1,3]thiazole-4,9-diones 1.
Scheme 4: Synthesis of 2,3-dihydroanthra[2,3-d][1,3]thiazole-4,11-diones 2.
Scheme 5: Reaction of N-substituted 2-(methylamino)anthracene-1,4-diones 4 with S2Cl2 and Hünig’s base.
Scheme 6: Synthesis of thiazole-2-thiones 10c and 11 from quinonothiazoles 1c and 2c.
Scheme 7: A plausible mechanism for the formation of naphtho- and anthraquinonothiazoles.
Scheme 8: Synthesis of 5-methyl-2,3,4,5-tetrahydro-1H-benzo[b]carbazole-6,11-dione (15) and 5-methyl-2,3,4,5-...
Scheme 9: A plausible mechanism for the conversion of spiro compounds 1d or 2d into carbazolediones 15 and 16....
Beilstein J. Org. Chem. 2012, 8, 25–49, doi:10.3762/bjoc.8.4
Graphical Abstract
Figure 1: Schematic representation of organic D-π-A system featuring ICT.
Figure 2: Two principal orientations of the imidazole-derived charge-transfer chromophores.
Scheme 1: Common synthetic approach to triarylimidazole-, diimidazole-, and benzimidazole-derived CT chromoph...
Scheme 2: Syntheses of important 4,5-dicyanoimidazole derivatives 1–3 [27-30].
Figure 3: Donor–acceptor triaryl push–pull azoles 4a–h [31,32].
Figure 4: Y-shaped CT chromophores with an extended π-conjugated pathway and various donor and acceptor subst...
Figure 5: Molecular structures of chromophores 9–14 [13,15,37-41].
Figure 6: General structure of 4,5-bis(4-aminophenyl)imidazole-derived chromophores 15a–g with various π-link...
Figure 7: Various orientations of the substituents on the parent lophine π-conjugated backbone (16–19) and th...
Figure 8: Structure and electronic absorption spectra of chromophores 21–26 [12].
Figure 9: Typical D-π-A diimidazole CT chromophore [16-18,50-53].
Figure 10: Typical D-π-D diimidazoles 28–31 [19,54-56] and photochromic diimidazoles 32,33 [57,58].
Scheme 3: Oxidation of 1H-diimidazoles to 2H-diimidazoles (quinoids).
Figure 11: Typical benzimidazoles-derived D-π-A push–pull systems 35–43 [25,62-66].
Figure 12: Structure of benzimidazoles (44–47), imidazophenanthrolines (48–57), imidazophenanthrenes (58–60), ...
Scheme 4: Acidoswitchable NLO-phores 64,65 and ESIPT mechanism [72-74].
Figure 13: General structures of bis(benzimidazole) chromophores 67–71 and pyridinium betaines 72 [75-79].
Figure 14: Overview of 4,5-dicyanoimidazole derivatives investigated by Rasmussen et al. [29,81-94].
Figure 15: 4,5-Dicyanoimidazole-derived chromophores 84–87 [103-106].
Figure 16: Push–pull chromophores 88–93 with systematically extended π-linker [30].
Figure 17: pH-triggered NLO switches 88c–93c [109].
Figure 18: Dibromoolefin 94 and branched chromophores 95–100 [112,113].
Figure 19: Imidazole as a donor–acceptor unit in CT-chromophores 101–111 [20].
Figure 20: Diimidazoles 112–115 used as small electron acceptors in organic solar cells [115,116].
Figure 21: Amino- and hydroxy-functionalized chromophores incorporated into a polymer backbone Rpol [18,50-53,122-124].
Figure 22: Structure of polyphosphazene polymers bearing NLO-phores [125-127] and some other recent examples of nonline...
Figure 23: Epoxy- and silica-based polymers functionalized with 4,5-dicyanoimidazole unit [105,130].
Beilstein J. Org. Chem. 2011, 7, 1584–1601, doi:10.3762/bjoc.7.187
Graphical Abstract
Scheme 1: Stoichiometric and catalytic direct (hetero)arylation of arenes.
Scheme 2: Stille and Negishi cross-coupling methodologies in oxazole series [28,30,31,33,34].
Scheme 3: Stoichiometric direct (hetero)arylation of (benz)oxazole with magnesate bases [35].
Scheme 4: Ohta's pioneering catalytic direct C5-selective pyrazinylation of oxazole [36,37].
Scheme 5: Preparation of pharmaceutical compounds by following the pioneering Ohta protocol [38,39].
Scheme 6: Miura’s pioneering catalytic direct arylations of (benz)oxazoles [40]. aIsolated yield.
Scheme 7: Pd(0)- and Cu(I)-catalyzed direct C2-selective arylation of (benz)oxazoles [41-44].
Scheme 8: Cu(I)-catalyzed direct C2-selective arylations of (benz)oxazoles [40,45-47].
Scheme 9: Copper-free Pd(0)-catalyzed direct C5- and C2-selective arylation of oxazole-4-carboxylate esters [48-50,52].
Scheme 10: Iterative synthesis of bis- and trioxazoles [51].
Scheme 11: Preparation of DPO- and POPOP-analogues [53].
Scheme 12: Pd(0)-catalyzed direct arylation of benzoxazole with aryl chlorides [54].
Scheme 13: Pd(0)-catalyzed direct C2-selective arylation of (benz)oxazoles with bromides and chlorides using b...
Scheme 14: Palladium-catalyzed direct arylation of oxazoles under green conditions; (a) Zhuralev direct arylat...
Scheme 15: Pd(0)-catalyzed C2- and C5-selective (hetero)arylation of oxazole [63].
Scheme 16: Pd(0)-catalyzed C2- and C5-selective (hetero)arylation of ethyl oxazole-4-carboxylate [64].
Scheme 17: Pd(0)-catalyzed direct C4-phenylation of oxazoles; (a) Miura’s procedure [65]; (b) Fagnou’s procedure [66].
Scheme 18: Catalytic cycles for Cu(I)-catalyzed (routeA) and Pd(0)/Cu(I)-catalyzed (route B) direct arylation ...
Scheme 19: Base-assisted, Pd(0)-catalyzed, C2-selective, direct arylation of benzoxazole proposed by Zhuralev [58]...
Scheme 20: Electrophilic substitution-type mechanism proposed by Hoarau [64].
Scheme 21: CMD-proceeding C5-selective direct arylation of oxazole proposed by Strotman and Chobabian [63].
Scheme 22: DFT calculations on methyl oxazole-4-carboxylate and consequently developed methodologies for the P...
Scheme 23: Pd(0)-catalyzed direct arylation of (benz)oxazoles with tosylates and mesylates [71].
Scheme 24: Pd(0)-catalyzed direct arylation of oxazoles with sulfamates [72].
Scheme 25: Pd(II)- and Cu(II)-catalyzed decarboxylative direct C–H coupling of oxazoles with 4- and 5-carboxyo...
Scheme 26: Pd(II)- and Ag(II)-catalyzed decarboxylative direct arylation of (benzo)oxazoles [74]; (a) procedure; (...
Scheme 27: Pd(II)- and Cu(II)-catalyzed direct arylation of benzoxazole with arylboronic acids [76]; (a) procedure...
Scheme 28: Ni(II)-catalyzed direct arylation of benzoxazoles with arylboronic acids under O2 [76]; (a) procedure; ...
Scheme 29: Rhodium-catalyzed direct arylation of benzoxazole [78,79].
Scheme 30: Ni(II)-catalyzed direct arylation of (benz)oxazoles with aryl halides; (a) Itami's procedure [80]; (b) ...
Scheme 31: Dehydrogenative cross-coupling of (benz)oxazoles; (a) Pd(II)- and Cu(II)-catalyzed cross-coupling o...
Beilstein J. Org. Chem. 2011, 7, 980–987, doi:10.3762/bjoc.7.110
Graphical Abstract
Scheme 1: Povarov oxidation access to substituted quinolines.
Scheme 2: Tetrahydroquinoline oxidation.
Scheme 3: Synthesis of the Povarov adducts and their oxidation products.
Figure 1: Optimization of the reaction conditions for the preparation of quinoline 18.
Scheme 4: Oxidation of lactam-fused tetrahydroquinolines 20,20'.
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2010, 6, 880–921, doi:10.3762/bjoc.6.88
Graphical Abstract
Figure 1: Examples of industrial fluorine-containing bio-active molecules.
Figure 2: CF3(S)- and CF3(O)-containing pharmacologically active compounds.
Figure 3: Hypotensive candidates with SRF and SO2RF groups – analogues of Losartan and Nifedipin.
Figure 4: The variety of the pharmacological activity of RFS-substituted compounds.
Figure 5: Recent examples of compounds containing RFS(O)n-groups [12-18].
Scheme 1: Fluorination of ArSCCl3 to corresponding ArSCF3 derivatives. For references see: a[38-43]; b[41,42]; c[43]; d[44]; e[38-43,45-47]; f[38-43,48,49]; g...
Scheme 2: Preparation of aryl pentafluoroethyl sulfides.
Scheme 3: Mild fluorination of the aryl SCF2Br derivatives.
Scheme 4: HF fluorinations of aryl α,α,β-trichloroisobutyl sulfide at various conditions.
Scheme 5: Monofluorination of α,α-dichloromethylene group.
Scheme 6: Electrophilic substitution of phenols with CF3SCl [69].
Scheme 7: Introduction of SCF3 groups into activated phenols [71-74].
Scheme 8: Preparation of tetrakis(SCF3)-4-methoxyphenol [72].
Scheme 9: The interactions of resorcinol and phloroglucinol derivatives with RFSCl.
Scheme 10: Reactions of anilines with CF3SCl.
Scheme 11: Trifluoromethylsulfanylation of anilines with electron-donating groups in the meta position [74].
Scheme 12: Reaction of benzene with CF3SCl/CF3SO3H [77].
Scheme 13: Reactions of trifluoromethyl sulfenyl chloride with aryl magnesium and -mercury substrates.
Scheme 14: Reactions of pyrroles with CF3SCl.
Scheme 15: Trifluoromethylsulfanylation of indole and indolizines.
Scheme 16: Reactions of N-methylpyrrole with CF3SCl [80,82].
Scheme 17: Reactions of furan, thiophene and selenophene with CF3SCl.
Scheme 18: Trifluoromethylsulfanylation of imidazole and thiazole derivatives [83].
Scheme 19: Trifluoromethylsulfanylation of pyridine requires initial hydride reduction.
Scheme 20: Introduction of additional RFS-groups into heterocyclic compounds in the presence of CF3SO3H.
Scheme 21: Introduction of additional RFS-groups into pyrroles [82,87].
Scheme 22: By-products in reactions of pyrroles with CF3SCl [82].
Scheme 23: Reaction of aromatic iodides with CuSCF3 [93,95].
Scheme 24: Reaction of aromatic iodides with RFZCu (Z = S, Se), RF = CF3, C6F5 [93,95,96].
Scheme 25: Side reactions during trifluoromethylsulfanylation of aromatic iodides with CF3SCu [98].
Scheme 26: Reactions with in situ generated CuSCF3.
Scheme 27: Perfluoroalkylthiolation of aryl iodides with bulky RFSCu [105].
Scheme 28: In situ formation and reaction of RFZCu with aryl iodides.
Figure 6: Examples of compounds obtained using in situ generated RFZCu methodology [94].
Scheme 29: Introduction of SCF3 group into aromatics via difluorocarbene.
Scheme 30: Tetrakis(dimethylamino)ethylene dication trifluoromethyl thiolate as a stable reagent for substitut...
Scheme 31: The use of CF2=S/CsF or (CF3S)2C=S/CsF for the introduction of CF3S groups into fluorinated heteroc...
Scheme 32: One-pot synthesis of ArSCF3 from ArX, CCl2=S and KF.
Scheme 33: Reaction of aromatics with CF3S− Kat+ [115].
Scheme 34: Reactions of activated aromatic chlorides with AgSCF3/KI.
Scheme 35: Comparative CuSCF3/KI and Hg(SCF3)2/KI reactions.
Scheme 36: Me3SnTeCF3 – a reagent for the introduction of the TeCF3 group.
Scheme 37: Sandmeyer reactions with CuSCF3.
Scheme 38: Reactions of perfluoroalkyl iodides with alkali and organolithium reagents.
Scheme 39: Perfluoroalkylation with preliminary breaking of the disulfide bond.
Scheme 40: Preparation of RFS-substituted anilines from dinitrodiphenyl disulfides.
Scheme 41: Photochemical trifluoromethylation of 2,4,6-trimercaptochlorobenzene [163].
Scheme 42: Putative process for the formation of B, C and D.
Scheme 43: Trifluoromethylation of 2-mercapto-4-hydroxy-6-trifluoromethylyrimidine [145].
Scheme 44: Deactivation of 2-mercapto-4-hydroxypyrimidines S-centered radicals.
Scheme 45: Perfluoroalkylation of thiolates with CF3Br under UV irradiation.
Scheme 46: Catalytic effect of methylviologen for RF• generation.
Scheme 47: SO2−• catalyzed trifluoromethylation.
Scheme 48: Electrochemical reduction of CF3Br in the presence of SO2 [199,200].
Scheme 49: Participation of SO2 in the oxidation of ArSCF3−•.
Scheme 50: Electron transfer cascade involving SO2 and MV.
Scheme 51: Four stages of the SRN1 mechanism for thiol perfluoroalkylation.
Scheme 52: A double role of MV in the catalysis of RFI reactions with aryl thiols.
Scheme 53: Photochemical reaction of pentafluoroiodobenzene with trifluoromethyl disulfide.
Scheme 54: N- Trifluoromethyl-N-nitrosobenzene sulfonamide – a source of CF3• radicals [212,213].
Scheme 55: Radical trifluoromethylation of organic disulfides with ArSO2N=NCF3.
Scheme 56: Barton’s S-perfluoroalkylation reactions [216].
Scheme 57: Decarboxylation of thiohydroxamic esters in the presence of C6F13I.
Scheme 58: Reactions of thioesters of trifluoroacetic and trifluoromethanesulfonic acids in the presence of ar...
Scheme 59: Perfluoroalkylation of polychloropyridine thiols with xenon perfluorocarboxylates or XeF2 [222,223].
Scheme 60: Interaction of Xe(OCORF)2 with nitroaryl disulfide [227].
Scheme 61: Bi(CF3)3/Cu(OCOCH3)2 trifluoromethylation of thiophenolate [230].
Scheme 62: Reaction of fluorinated carbanions with aryl sulfenyl chlorides.
Scheme 63: Reaction of methyl perfluoromethacrylate with PhSCl in the presence of fluoride.
Scheme 64: Reactions of ArSCN with potassium and magnesium perfluorocarbanions [237].
Scheme 65: Reactions of RFI with TDAE and organic disulfides [239,240].
Scheme 66: Decarboxylation of perfluorocarboxylates in the presence of disulfides [245].
Scheme 67: Organization of a stable form of “CF3−” anion in the DMF.
Scheme 68: Silylated amines in the presence of fluoride can deprotonate fluoroform for reaction with disulfide...
Figure 7: Other examples of aminomethanols [264].
Scheme 69: Trifluoromethylation of diphenyl disulfide with PhSO2CF3/t-BuOK.
Scheme 70: Amides of trifluoromethane sulfinic acid are sources of CF3− anion.
Scheme 71: Trifluoromethylation of various thiols using “hyper-valent” iodine (III) reagent [279].
Scheme 72: Trifluoromethylation of p-nitrothiophenolate with diaryl CF3 sulfonium salts [280].
Scheme 73: Trifluoromethyl transfer from dibenzo (CF3)S-, (CF3)Se- and (CF3)Te-phenium salts to thiolates [283].
Scheme 74: Multi-stage paths for synthesis of dibenzo-CF3-thiophenium salts [61].
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
Beilstein J. Org. Chem. 2006, 2, No. 21, doi:10.1186/1860-5397-2-21
Graphical Abstract
Figure 1: Thiazolidine-2,4-dione mimic & chosen lead scaffold.
Scheme 1: Reagents and conditions: (a) PS-PPh3, DEAD, THF, rt, 16 h, 54%.
Figure 2: Proposed mechanism of the Mitsunobu reaction.
Scheme 2: Reagents and conditions: (a) PS-PPh3, ADDP, THF, rt, 16 h, 81%.
Scheme 3: Reagents and conditions: (a) 1 N aq. NaOH, MeCN, 100°C μW, 10 mins, 96%.